Needham & Company LLC Reiterates “Buy” Rating for Immuneering (NASDAQ:IMRX)
Immuneering (NASDAQ:IMRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $9.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of […]
Immuneering (NASDAQ:IMRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $9.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of […]
